Table 2. Univariate analysis to estimate the risk of various factors for nephrolithiasis.
| Hazard ratio | 95%CI | P value | |
|---|---|---|---|
| ATV/r use over DRV/r | 26.01 | 3.541-191.0 | 0.001 |
| Age per 1 year | 1.002 | 0.973-1.031 | 0.907 |
| Male sex | 1.665 | 0.401-6.919 | 0.483 |
| Race (East Asian origin) | 2.287 | 0.314-16.68 | 0.414 |
| Weight per 1 kg increment | 0.998 | 0.970-1.027 | 0.872 |
| body mass index per 1 kg/m2 increment | 0.996 | 0.905-1.095 | 0.927 |
| CD4 count per 10 /μl increment | 0.999 | 0.983-1.016 | 0.901 |
| HIV viral load per log10/ml | 1.063 | 0.859-1.316 | 0.575 |
| Treatment naïve | 1.020 | 0.538-1.936 | 0.950 |
| Tenofovir use | 0.435 | 0.210-0.899 | 0.025 |
| Baseline eGFR per 10 ml/min/1.73 m2 decrement | 1.103 | 0.980-1.242 | 0.105 |
| Baseline serum uric acid per 1 mg/dl increment | 1.415 | 1.173-1.705 | <0.001 |
| Hepatitis B or Hepatitis C | 1.418 | 0.592-3.393 | 0.433 |
| Past history of renal stone | 2.658 | 1.111-6.359 | 0.028 |
| Previous exposure to IDV | 1.192 | 0.366-3.879 | 0.771 |
ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; HIV, human immunodeficiency virus; eGFR, estimated glomerular filtration rate; IDV, indinavir.